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Background: Clinical trials involving children previously considered unethical are now considered essential because
of the inherent physiological differences between children and adults. An integral part of research ethics is the
informed consent, which for children is obtained by proxy from a consenting parent or guardian. The informed
consent process is governed by international ethical codes that are interpreted in accordance with local laws and
procedures raising the importance of contextualizing their implementation.
Findings: In Zimbabwe the parental informed consent document for children participating in clinical research is
modeled along western laws of ethics and requires that the parent or legally authorized representative provide
consent on behalf of a minor. This article highlights the experiences and lessons learnt by Zimbabwean researchers
in obtaining informed consent from guardians of orphaned children participating in a collaborative HIV clinical trial
involving the Medical Research Council, United Kingdom and four centers, three of which are in Uganda.
Researchers were faced with a situation where caregivers of orphaned children were not permitted to provide
informed consent for trial participation. The situation contrasted with general clinical practice where consent for
procedures on orphans is obtained from their caregivers who are not legal guardians.
Conclusion: The challenges faced in obtaining informed consent for orphans in this clinical trial underscores the
need for the Zimbabwe ethics committee to develop an ethical and legal framework for pediatric research that is
based on international guidelines while taking into account the cultural context. The Medical Research Council of
Zimbabwe has since started the process that is expected to involve critical stakeholders namely the community
including children, ethicists, the legal fraternity and researchers.Background
Research in human participants is governed by inter-
national ethical codes and legislation derived from the
basic moral principles of autonomy, beneficence and
justice. The responsibility for research participant pro-
tection lays with ethics committees (EC) and institu-
tional review boards (IRB) whose mandate is to review
research projects for their scientific merit and clinical
usefulness. One of the key responsibilities of ECs in* Correspondence: dangas@zol.co.zw
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distribution, and reproduction in any mediumprotecting human participants is review of the informed
consent process to ensure that accurate information
about the study and its purpose are conveyed, including
known risks, benefits and alternatives; that procedures
are disclosed, and questions are answered, thus enabling
the participant to make an informed decision about
whether or not to participate [1]. Certain groups are
considered vulnerable research participants because they
may have insufficient power, intelligence, education,
resources, strength or other necessary attributes to pro-
tect their own interests [1]. Children, defined as persons
who have not attained the legal age of consent, belong
to this vulnerable group and consent is obtained byBioMed Central Ltd. This is an Open Access article distributed under the terms
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cordance with local laws or established procedures [1]
The parents or legal guardian are expected to act in the
best interests of the child throughout the research. An
additional challenge faced in conducting research that
involves children is achieving the balance between the
social good that comes from children’s participation and
offering the appropriate level of protection to them.
Major research groups and professional bodies world-
wide such as the National Institutes of Health (NIH)
in the USA, The Medical Research Council (MRC) in
the UK and The Royal College of Pediatrics and Child
Health (RCPCH) in the UK, have published policy
statements on the importance of assessing health-care
interventions for use in children through randomized
controlled trials [2]. This has arisen from the under-
standing that children are physiologically, developmen-
tally and emotionally different from adults and
developing treatments for children by extrapolating
results from adult studies may actually impose harm [3].
Protection of children from exploitation has remained
central leading to the inclusion of assessing risk versus
benefit of research involving children. The US Federal
Policy for the Protection of Human Subjects has defined
four categories where research in children may be con-
ducted [4]. These are minimal risk, greater than minimal
risk and prospect of direct benefit, greater than minimal
risk and no prospect of direct benefit and research not
otherwise approvable. Ethics committees are given the
responsibility for determining these risk categories. The
MRC Ethics Guide for medical research involving chil-
dren also upholds minimizing risk and assessing poten-
tial benefits of research not only for the participant but
for children as a whole [5] Such frameworks may not be
developed to the same level and tend to lag behind in
developing countries where an increasing amount of
pediatric research takes place. An example is the separ-
ation of ‘therapeutic’ and non-therapeutic research’
which is no longer used in the Declaration of Helsinki
(2002) but is still in use in some countries including
Zimbabwe. The recent globalization of health has seen
more research involving children taking place in devel-
oping countries through collaborations between devel-
oped and developing countries to the mutual benefit of
both. This move is an attempt to redress the global in-
equity in research dubbed the ‘10/90’ gap in which less
than 10% of the estimated US$70 billion spent annually
on health research addresses the conditions that account
for 90% of the global disease burden, measured by the
number of disability-adjusted-life-years [6]. Generally,
collaborative studies must have ethical approval from
the sponsoring country as well as the country or institu-
tions where the research will be conducted. This brings
together ethical standards from different socio-culturalbackgrounds. Ethics committees in both the sponsor
country and the host country have the responsibility to
ensure scientific and ethical review as well as the author-
ity to deny approval of research protocols that fail to
meet their scientific or ethical standards [2]. Ethics com-
mittees in the host country must, in addition, determine
whether the research objectives are responsive to the
local health needs and priorities. According to the Coun-
cil for International Organizations of Medical Sciences
(CIOMS) guidelines of 2002, the EC in the host country
can be expected to have greater competence for review-
ing the detailed plans for compliance, in view of its bet-
ter understanding of the cultural and moral values of the
population in which it is proposed to conduct the re-
search [2]. The host country is also likely to be in a bet-
ter position to monitor compliance during the course of
a study. The importance of taking into account the con-
text within which research is conducted has been high-
lighted in research conducted in other developing
countries. Individual decision-making characterizes the
informed consent process in developed western coun-
tries unlike the family and community participation in
some Asian and African countries [7,8]. South Africa is
one developing country that has made some progress in
addressing consenting issues for children in their Chil-
dren’s Act of 2005 [9] that allows children to consent in-
dependently to health-related interventions such as male
circumcision and HIV testing. In addition to parents and
legal guardians, the act has made provision for care-
givers such as grandparents or other relatives who do
not have parental responsibilities and rights but are able
to provide proxy consent on behalf of minors [10]. This
is an innovative development that acknowledges the
reality that a significant number of children will be taken
care of by caregivers such as grandparents or other rela-
tives. The legal framework for health research in South
Africa does not however have provision for children to
consent to any form of health research and limits proxy
consent to parents and legal guardians leaving research
ethics committees to rely on the principles of ethical
guidelines.
In this paper, we discuss the experiences faced by
researchers in obtaining informed consent for orphaned
children in Zimbabwe and how this highlighted the need
to develop an ethico-legal framework to guide research-
involving minors that is sensitive to the socio-cultural
environment. We also offer some recommendations of
issues to be taken into consideration when ethics com-
mittees develop these guidelines.
Discussion
The ARROW clinical trial
Antiretroviral Research for Watoto (ARROW) is a phase III
multicenter clinical trial evaluating monitoring and first-
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children in Uganda and Zimbabwe [11]. This study is co-
sponsored by the United Kingdom (UK) Medical Research
Council (MRC) and the UK Department for International
Development (DFID). A Trial Steering Committee (TSC)
comprising independent members from the three coun-
tries, the principal investigators and an independent chair
govern the ARROW trial. The TSC supervises the progress
of the trial towards its interim and overall objectives, focus-
ing on adherence to the protocol, Good Clinical Practice,
patient safety and the consideration of new information
[11]. The Researchers from United Kingdom, Uganda and
Zimbabwe were involved in drafting the main protocol and
developing information sheets together with consent forms
for parents or caregivers as well as children who had
reached the level of assent. These documents were trans-
lated into the respective local languages before submission
to Ethics Committees for review and approval. ARROW
received approval from the Ugandan EC and Zimbabwean
ECs in February and March 2006 respectively.
Current governance of research and informed consent for
children in Zimbabwe
The Medical Research Council of Zimbabwe (MRCZ), the
National Ethics Committee was established in 1974 under
the Research Act of 1959 and Government Notice Number
225 of 1974 in order to provide health researchers and
institutions conducting health research with independent
ethical advice on research [12]. It is composed of scientists,
medical experts, ethicists, lawyer and religious and commu-
nity representatives, making a total of 14 members. The
Medicines Control Authority of Zimbabwe (MCAZ) regu-
lates all clinical trials that are conducted in Zimbabwe in
terms of Part III of the Medicines and Allied Substances
Control Act [Chapter 15:03] [13]. There are no specific laws
that are dedicated to research involving children in
Zimbabwe. However there are two acts that relate to con-
sent of minors in clinical trials and in organ donation or re-
moval. The Medicines and Allied Substances Control Act
Chapter 3:20 pertains to consent of minors in clinical trials
and says;
“Where the Council grants written authorisation under
section eighteen for the conduct of a trial of a drug, no
such trial shall take place until -
b) in the case of a medicine for the treatment of
minors or persons under legal disability, the voluntary
written consents of their parents or legal guardians, as
the case may be, have been freely obtained by the
person conducting the trial.
The Anatomical Donations and Post-Mortem Exami-
nations Act [14] says;“Replacement tissue may be removed from the body of
a living person for scientific purposes or therapeutic
purposes-
12 b) in the case of a person under the age of eighteen
years, whether or not he is capable of expressing his
consent, with the written consent of his parents or
guardian:
Both these acts are not specific for research involving
children and do not refer to the child’s assent or the
child’s best interest. In addition the term legal guardian
is interpreted using legal terminology.
The MRCZ requires that parental informed consent be
obtained from the parent of the child or a legally author-
ized representative. A third party can be appointed
guardian of a minor child where there is no natural par-
ent alive or where the natural parent may be alive but it
is not in the best interests of the child that they be
vested with guardianship of the child and where the
available natural guardian does not have the capacity to
act as such. The appointment of such a third party is
made through a court application outlined below.
 A relative or person having the care and custody of
the child lodges an application with the clerk of court
for the appointment of a person as guardian of the
minor with the following accompanying documents:
 Death certificates to prove that the child’s parents
were both deceased.
 The child’s birth certificate.
 Four supporting affidavits, two each from the
maternal and paternal relatives
The clerk of court would then publish in the Govern-
ment Gazette and any other national newspaper circulat-
ing in the area where the minor resides calling upon any
person interested in the matter to appear before the chil-
dren’s court on a date specified in the notice and specify-
ing the name of a person proposed for appointment as
the guardian. The time period given for the response is
not less than 7 days and not more than 30 days after
publication of the notice. The clerk of court then issues
a letter of appointment to the person appointed as
guardian specifying the powers, rights and privileges
conferred upon that person. In situations where the con-
senting parent dies, the statutes regulating the appoint-
ment of guardians come into effect. These are the
Guardianship of Minors Act, Child Protection and
Adoption Act and Administration of Deceased Estates
[15,16]. In cases where there is a surviving parent, she/
he takes over guardianship and provides the consent. If
the consenting parent who was a sole guardian dies, he/
she is expected to have had a will with provision for a
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in Zimbabwean African culture. Where the child is left
in the custody of relatives who are taking care of the
child, the responsible relative for all practical purposes
assumes the guardianship of the child, but must be con-
firmed by the court in terms of section 9 of the Chil-
dren’s Act. In Zimbabwean culture, the legal route is
rarely pursued where custody of children is concerned.
A child is placed in the custody of a relative or relatives
upon the death of the parents following consultation
with the extended family. This guardian takes over par-
ental responsibility of the child including schooling,
health care and in the case of the ARROW trial, also
took on consent for participation in research.
Challenges experienced in the ARROW trial
Screening and enrolment into the ARROW clinical trial
started rapidly in Uganda; however in Zimbabwe, it be-
came apparent that a substantial number of potential re-
search participants were orphans (120/400; 30%) whose
relatives wanted them to be involved in the study but
could not because of the requirement by the Law
(Guardianship of Minors Act Chapter 5:08) of Zimbabwe
for consent from a parent or legal guardian. The
researchers learnt that Zimbabwean law only recognized
a legal guardian as one who had been given custody of
the child by a court. Further enquiry from the legal fra-
ternity and children’s rights groups revealed that the
process was both lengthy and costly (estimated cost of
USD100 excluding legal fees). This legal process was
communicated to the caregivers of potential ARROW
participants most of whom were not only unaware of
the existence of legal guardianship requirements but
were also unwilling to engage in the process. The
researchers quickly realized that the unwillingness to
apply for legal guardianship was not related to the docu-
mentation required e.g. birth certificates as these could
be obtained easily through the government system.
Death certificates are also a legal requirement in
Zimbabwe. Only 1/120 (0.08%) orphans had a guardian
appointed by the court. In traditional Zimbabwean
African culture, children are viewed as belonging to the
community and surviving relatives are expected to take
care of a deceased relative’s children. This process does
not require formalization through the courts. An adult
relative is usually identified as the custodian following
the parents’ death with the realization that caring for
these children is a shared responsibility. Though
Zimbabwe is a patrilineal society, most of the orphaned
children were in the custody of their maternal relatives.
This may have been a reflection of the young age of the
children and the need for maternal input from the
mother’s side of the family. The researchers who were all
Zimbabweans were constrained by the realization thatwhile caregivers of children could provide consent for
treatment including surgery in general medical practice,
this was not so in research. They were now faced with a
situation where a substantial number of children whose
relatives were willing and enthusiastic to provide
informed consent for trial participation would be
excluded from the clinical trial. This was at a time when
the national ART roll-out for children had only just
started and was characterized by long waiting periods in
a health care delivery system that was going through
major challenges. The EC was informed of the chal-
lenges that were being faced and how the legal require-
ment could potentially disadvantage this group of
children who were already vulnerable by virtue of being
orphans. Among their considerations was the acknow-
ledgement that there was no framework governing re-
search involving children, the importance of not
stigmatizing orphans by denying them participation in
research that could potentially benefit them and the ab-
sence of direct benefits accruing to the caregivers. They
also considered what would be in the best interests of
the child as compared to fulfilling the requirements of
the law. While underscoring the importance of protect-
ing children in research, the EC eventually made a deci-
sion to provide a ‘waiver’ of the legal guardianship
requirement, but requested that care-givers sign an affi-
davit stating that they understood the high level of com-
mitment required of them during the ARROW clinical
trial. Custodians who were recognized by the family pro-
vided consent for the children’s participation in the
study. The site proceeded to implement the recommen-
dation and wherever possible engaged both the maternal
and paternal sides of an orphaned child’s families in the
information giving and consenting process. The site was
able to enroll 400 children, 40% were orphans into the
trial over the planned 15-month period.
During the course of the study, participants who lost a
surviving parent or guardian had to be re-consented for
continued participation by another custodian appointed
by the family. This re-consenting process would once
again include a child’s paternal and maternal relatives as
far as possible. Involvement of both sides of a child’s
family proved to be an asset because it ensured continu-
ity of care whenever the child visited other relatives (a
frequent occurrence) or there was change in guardian-
ship during the course of the trial. A total of 6 children
lost a surviving parent during the course of the clinical
trial and were consented for continuation in the trial by
relatives agreed upon by the family.
Recommendations
1. While it is generally accepted that informed consent
for children’s participation in research is obtained
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the Zimbabwe ethics committee had not foreseen
the challenge that researchers faced in adhering to
ethical principles within a cultural context that did
not recognize or practice legal adoption of orphaned
children. An ethical approach that is culturally
sensitive and yet adheres to universal ethical
standards of child health research [7] should be
adopted in the development of an ethico-legal
framework that guides research-involving children.
Researchers should also familiarize themselves with
the requirements for informed consent for
vulnerable groups that include children. Dialogue
has begun between the Zimbabwe ethics
committees, researchers and the legal fraternity with
a view to developing this framework.
2. The ARROW clinical trial demonstrated cultural
sensitivity in obtaining informed consent for
orphaned children by engaging the extended family.
Shaibu [7] also suggests this family-centered
approach to decision making from her experience in
obtaining informed consent in Botswana. It is
therefore recommended that the Zimbabwe ethics
committee find ways of obtaining community input
in the process of drafting the framework that will
govern pediatric research. In this age of international
collaborative research, it is important for sponsors
to have an appreciation of the cultural contexts
within which the studies will be conducted. The
consideration of ‘parental responsibilities and rights’
of caregivers by the South Africans in their revised
Children’s Act could also inform the debate on
consenting issues for research involving children
who do not have biological parents.
Summary
The globalization of research particularly in HIV/AIDS
calls for an urgent need for developing countries such as
Zimbabwe to develop a framework for pediatric research
that is based on international ethical guidelines but takes
into account the context of local cultural, medical and
legal systems. The experience in ARROW, one of the
large HIV pediatric clinical trials in Africa, has revealed
some deficiencies in the ethical and legal framework
governing research-involving children. Subsequent to
ARROW, a number of research teams have made similar
representations regarding obtaining informed consent for
orphans in clinical trials prompting the Medical Research
Council of Zimbabwe to re-examine the laws and policies
governing research involving children in Zimbabwe with
the assistance from the Attorney General’s office.
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